Previous close | 118.29 |
Open | 116.25 |
Bid | 116.59 x 200 |
Ask | 116.71 x 200 |
Day's range | 115.73 - 119.15 |
52-week range | 89.00 - 229.58 |
Volume | |
Avg. volume | 1,685,337 |
Market cap | 18.583B |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.
BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.
Investors shelved their hopes for a pioneering cancer blood test after Illumina ‘s $8 billion acquisition of start-up Grail was scuttled by antitrust regulators last year. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them. At the annual meeting of the American Association for Cancer Research in San Diego, Exact Sciences reported on a 6,000-sample study of a multi-cancer test it plans to offer alongside single-cancer screening products such as its well-known Cologuard stool-based test for colon cancer.